Sanofi-Aventis, one of the world's leading pharmaceutical companies, issued a press release that stated Taxotere (docetaxel) improves survival in patients with metastatic prostate cancer.
A Phase III clinical trial named TAX 327 compared Taxotere plus prednisone to Novantrone (mitoxantrone) plus prednisone. The study included a little over a thousand men who had recurrences or spread of disease after hormonal therapy.
The results of the study showed that survival was improved by 21 percent among patients treated with the Taxotere based therapy. The men also were without pain for a longer periods of time than those treated with Novantrone based therapy.
Researchers conclude that these long term results continue to provide evidence that Taxotere based therapy improves survival for advanced prostate cancer patients.
Source: Bio-Bio Technology